A summary of the latest developments from 12 studies on the use of BTKi and BCL2i for the treatment of B-cell malignancies and AML from ASH 2022.
Jake Shortt
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.